Unravelling Alzheimer's Disease: It's Not the Whole Story, but Aβ Still Matters

Abstract

In late 2016, we solicited a series of reviews covering the variety of processes that appeared to be involved in the pathogenesis of neurodegenerative disorders, particularly Alzheimer's disease (AD). These essays have appeared at regular intervals in The FASEB Journal. My instructions to the researchers were simply not to emphasize Aβ per se because there had been many reviews both supporting and questioning the etiologic role of Aβ in the late‐onset, sporadic form of AD, and reciting either of those scientific positions would be redundant. My colleagues responded admirably, and I believe that their contributions have significantly informed readers' awareness of the current state of knowledge of AD. I have written my epilogue from the perspective of an investigator interested in the role of protein aggregation in human disease and as a physician who may be charged with making a diagnosis and prescribing treatment for a patient. We do not yet have etiology‐based therapies of AD, but we continue to gain insight into the mechanisms responsible for synaptic loss and the consequent functional deterioration. A silver therapeutic bullet does not seem to be in the offing. It is more likely that an iterative approach will lead to the development of a group of treatments that are AD specific or applicable to various features of the entire class of neurodegenerative disorders. How and when those therapies succeed or fail will, in turn, provide additional insights into disease pathogenesis, which will inform the development of succeeding generations of therapeutics.—Buxbaum, J. N. Unravelling Alzheimer's disease: if's not the whole story, but Aβ still matters. FASEB J. 33, 9701–9705 (2019). http://www.fasebj.org

Inflammasome‐mediated innate immunity in Alzheimer's disease

“…This article was invited as part of the recent Alzheimer's Disease Review Series (103, 104) but was not available until after the series closed.…”

Predisposition to Alzheimer’s and Age-Related Brain Pathologies by PM2.5 Exposure: Perspective on the Roles of Oxidative Stress and TRPM2 Channel

“…Sporadic form, accounting for a vast majority of cases, results from aging, genetic [e.g. carrying apolipoprotein E (APOE) ε4 allele which is associated with a reduced capacity of clearing and degrading Aβ], and environmental risk factors that aggravate amyloidogenesis (Blennow et al, 2010;Buxbaum, 2019;Licher et al, 2019).…”

“…The direct toxicity of Aβ to synapses and neurons is well attested by in vitro studies exposing cultured neurons to Aβ alongside in vivo studies using various strains of transgenic AD mice that express AD-linked human mutant genes leading to elevated Aβ levels (e.g. APP/PS1, 5xFAD, or APOE ε4 mice) or wild-type animals, predominantly mice and rats, with intrahippocampal administration of neurotoxic Aβ (Blennow et al, 2010;Buxbaum, 2019). Recent studies have disclosed AD-related alterations in the genetic and functional profile of microglia, the immune-competent cells in the brain, and association of mutations in microglia-specific genes (e.g.…”

Snatched from oblivion: “second lives” of bespoke drugs

“…For one, The FASEB Journal published a series of Perspectives on Alzheimer's Disease in 2018 and 2019 that collectively conveyed findings and ideas other than the “standard model” of AD pathogenesis (tangled amyloid and/or tau protein). The editor of this series, Joel Buxbaum, concluded it with a superb, comprehensive overview but he and I were careful not to claim that the mere existence of alternative ideas constitutes evidence that the amyloid/tau hypotheses are invalid . Neither Dr Buxbaum nor I anticipated, when we launched this series, that during their publication we would witness several pharmaceutical companies dropping their lead drugs based on the amyloid/tau hypothesis, such corporate decisions not necessarily signifying that the hypothesis is wrong.…”